ServiziMenu principaleHome
Home > Past events > ABC1 > Programme
Share on Share on Facebook Twitter Share on Linkedin Print this page

ABC1 Programme

Wednesday, 2 November 2011

Registration opens for individuals participants and for groups

Thursday, 3 November 2011

 9:00 Satellite symposium Novartis Oncology organised by prIME Oncology
Redefining the management of advanced breast cancer
(Chair: A. Di Leo, IT)
  • Welcome and introduction (A. Di Leo, IT)
  • Persistent (and perplexing) questions about ER/PgR determinations (G. Viale, IT)
  • Audience questions and faculty panel discussion
  • Endocrine therapy: Past, present, and current limitations (C.A. Hudis, US)
  • Audience questions and faculty panel discussion
  • Overcoming endocrine therapy resistance: The role of mTOR pathway targeting (H.S. Rugo, US)
  • Endocrine therapy resistance: Practical considerations—A panel discussion
  • Concluding remarks (A. Di Leo, IT)

    Symposium faculty:

    Angelo Di Leo, Sandro Pitigliani Medical Oncology Unit, Ospedale Misericordia e Dolce, Prato, IT
    Clifford A. Hudis, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, US
    Hope S. Rugo, Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
    Giuseppe Viale, Department of Pathology an dLaboratory Medicine, European Institute of Oncology, Milan, IT
11:00  Satellite symposium, GlaxoSmithKline
Optimal use of anti-HER2 agents in HER2+ advanced breast cancer: Choosing the right treatment option for patients
(Chair: C. Jackisch, DE)
  • Opening remarks (C. Jackisch, DE)
  • Choosing the right option for HER2+/HR+ tumours: The role of targeted therapy in combination with endocrine therapy 
    (N. Harbeck, DE)
  • Key aspects of resistance to anti-HER2 therapy (C. Jackisch, DE)
  • Clinical debate:
    Choosing the right option after progression on trastuzumab plus chemotherapy: The role of lapatinib plus capecitabine 
    (H.S. Rugo, US and D. Cameron, UK)
  • Q&A and symposium close (C. Jackisch, DE)

    Symposium faculty:

    David Cameron, Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, UK
    Nadia Harbeck, Breast Centre, Department of Obstetrics and Gynaecology, University of Cologne, DE
    Christian Jackisch, Department of Obstetrics and Gynaecology and Breast Cancer Klinikum Offenbach GmbH, Offenback, DE
    Hope S. Rugo, Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
12:30 Welcome lunch offered by GlaxoSmithKline 
13:30 Opening and introduction (F. Cardoso, PT)
13:45 Opening session (Chair: K. Redmond, CH)
  • Welcome to Lisbon (L. Beleza, PT (President, Champalimaud Foundation)
  • Keynote lecture
    Living with advanced breast cancer: Challenges and opportunities (M. Mayer, US) 
  • Panel discussion (K. Redmond, CH - F. Cardoso, PT - S. Kyriakides, CY - B. Borisch, CH - M. Mayer, US - L. Norton, US - E.P. Winer, US)
14:45 Basic research (part I) (Chair: L. Norton, US)
  • Metastasis seed pre-selection driven by the microenvironment
    of primary tumors (X. Zhang, US)
  • Tissue-specific metastases (R. Gomis, ES)
  • Angiogenesis and metastasis (D.C. Lyden, US)
  • Discussion
  • Basic Research - Best abstract presentation

    Primary Tumor in Breast Cancer (BC) and phenotype in positive lymphnodes and later disease recurrence (metastatic breast cancer, MBC): results of the PriMet-trial (WSG / DETECT) (R. Wuerstlein, DE)
16:35 Coffee break
17:00 Basic research (part II) (Chair: L. Norton)
  • Genomic signatures of specific sites of metastases (L. van't Veer, US) 
  • Mathematical model metastases (L. Norton, US)
  • Biology of metastases (J.F. Bromberg, US)
  • Breast stem cells and metastasis (S. Pece, IT)
  • Discussion
19:00 Satellite symposium, AstraZeneca
Optimising the use of endocrine therapy in the treatment of advanced breast cancer: Right patient, right treatment
(Chair: N. Harbeck, DE)
  • Treatment guidelines in ABC, on paper and in practice (A. Llombart Cussac, ES)
  • Faculty discussion
  • New endocrine treatment options in ABC – A personal perspective (J. Pippen, US)
  • Looking ahead – What does the future hold for endocrine therapy in ABC? (T. Bachelot, FR)

    Symposium faculty:

    Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne, DE
    Antonio Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES
    John Pippen, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, US
    Thomas Bachelot, Centre Léon Bérard, Lyon, FR
20:30 Welcome cocktail
Concert: Ana Moura, an internationally recognised Portuguese fado singer

Friday, 4 November 2011

 8:30 Exhibition
 8:30 Imaging and pathology for the management of advanced breast cancer (Chair: J. Bergh, SE)
  • Role of pathology in the management of advanced breast cancer (G. Viale, IT)
  • Overview of imaging tests for assessment of metastases in breast cancer (N. Houssami, AU)
 9:40 HER-2+ advanced breast cancer (Chair: E.P. Winer, US)
  • State-of-the-art management of HER-2+ disease (F. Cardoso, PT)
  • Resistance to anti-HER2 therapies (G.W. Sledge, US)
  • New and future therapies for HER-2+ advanced breast cancer (I.E. Krop, US)
  • Discussion
10:50 Coffee break
11:15 Triple-negative breast cancer (Chair: A. Goldhirsch, IT)
  • State-of-the-art management of TN disease (E.P. Winer, US)
  • Role of PARP inhibitors in TN advanced breast cancer (A. Tutt, UK)
  • Other targets beyond PARP for TN disease (A. Di Leo, IT)
  • Discussion
12:30  Lunch offered by Boehringer Ingelheim and
Poster session (see the list at the bottom of the page)
13:45 Best abstract presentations (Chair: L. Norton, US)
  • Clinical research
    Which benefit from subsequent chemotherapy lines beyond the second for women with metastatic breast cancer? Evidence from a single-center retrospective analysis of survivorship. (F. Sottotetti, IT)
  • Patient advocacy
    Silent Voices: accessing and meeting the information, support and practical services needs for women living with metastatic breast cancer (E.S. Caplan, US)
14:15 Challenges in the management of advanced breast cancer patients (Chair: A. Costa, IT/CH)
  • Is there still a role for radiotherapy in advanced breast cancer? (A. Rodger, UK)
  • Relevant endpoints for advanced breast cancer patients (P. Ganz, US)
  • Differencies in side effects assessment among doctors,
    nurses and patients (L. Fallowfield, UK)
  • Managing breast cancer in low- and middle-income countries (N. El Saghir, LB)
  • Managing costs in higher-income countries (D.A. Cameron, UK)
  • Discussion
15:50 Coffee break
16:10 Specific sites and specific populations (Chair: F. Cardoso, PT)
  • Bone metastases (R.E. Coleman, UK)
  • Brain metastases (N.U. Lin, US)
  • Role of primary site local management for advanced breast cancer patients (V. Sacchini, US)
  • Elderly patients (P. Francis, AU)
  • Very young patients (below 35) (K. Gelmon, CA)
  • Discussion
17:40 ER+ advanced breast cancer (Chair: B. Kaufman, IL)
  • State-of-the-art HT treatment in ER+ disease (O. Pagani, CH)
  • Endocrine resistance mechanisms and solutions (B. Kaufman, IL)
  • Role of chemotherapy in the management of ER+ disease (C.A. Hudis, US)
  • New and future therapies for ER+ advanced breast cancer (N. Harbeck, DE)
  • Discussion
19:00 Satellite symposium, EISAI
Embracing Life with Advanced Breast Cancer
(Chair: M. Untch, DE)
  • Welcome and introduction (M. Untch, DE)
  • The challenges of treating advanced breast cancer: Is overall survival an achievable aim? Evidence from the EMBRACE trial (J. Cortés, ES)
  • Reflecting on the real-world evidence for a new approach – eribulin case series (A. Awada, BE and H.S. Rugo, US), with faculty discussion led by M. Untch, DE
  • Re-defining the management of advanced breast cancer – Faculty discussion led by M. Untch, DE

    Symposium faculty:

    Ahmad Awada, Medical Oncology Clinic, Jules Bordet Institute, Brussels, BE
    Javier Cortés, Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, ES
    Hope S. Rugo, Department of Medicine (Haematology/Oncology), UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, US
    Michael Untch, Interdisciplinary Breast Cancer Center, HELIOS Hospital, Berlin, DE

Saturday, 5 November 2011

 9:00  Exhibition
 9:00  Consensus session (Part I) (Chairs: A. Costa, IT/CH - L. Norton, US)
Introduction by A. Cervantes, ES
  The panel will develop consensus recommendations for the management of advanced breast cancer continuing the work developed so far by the ESO-MBC Guidelines Task Force. A consensus manuscript will be published after the meeting in The Breast – exclusive partner journal of the conference.
10:30 Coffee break 
11:00 Consensus session (Part II) (Chairs: F. Cardoso, PT - E.P. Winer, US)
12:30  Close

Poster session

 BP32    Change in triple-receptor status between primary and recurrent breast cancer: prognostic impact. Maria Vittoria Dieci, IT
 BP53   BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer refractory to letrozole or anastrozole. Hope S. Rugo, US
 BP120   International survey identifies key support and lifestyle needs of metastatic breast cancer (MBC) patients. CJ (Dian) Corneliussen-James, US
 PO33    Leptin  and  leptin receptor  expression in  patients with breast cancer and fibroadenoma of different hormonal status. Dmitry Kravchenko, RU
 PO34   Expression of MAGE-A10 cancer/testis antigens in breast cancer: a retrospective immunohistochemical study. Antonio Juretic, HR
 PO35   Progestogen can stimulate growth factor production in breast tissue of women with breast cancer. Mia Fahlén, SE
 PO36   Prognostic significance of GRP78 expression patterns advanced breast cancer. Sophie Derchain, BR
 PO37    Correlation between p53 protein expression and other molecular markers influencing the metastatic breast cancer outcomes. Sigita Liutkauskiene, LT
 PO38   Lymphocyte subpopulations in peripheral blood of breast cancer patients. Lidia Skotarenko, RU
 PO39   Loss of TRAP1 expression as a possible mechanism behind recurrence risk in advanced breast cancer. Ern YuTan, SG
 PO40   Ki-67 expression predicts clinical outcome in locally advanced breast cancer. Naomi Kobayashi, JP
 PO41    Corelation between microvascular density (MVD) with the time to appearance of the metastasis in the patients with breast cancer. Zdenka Gojkovic, BA
 PO42   Fulvestrant: analysis of tumour biomarker expression in a combined analysis of pre-surgical studies. John F.R. Robertson, UK
 PO43    Integrate: a new model in collaborative breast cancer research. Lina Pugliano, BE
 PO44    A Japanese case of breast cancer with BRCA1 mutation. Noriko Miwa, JP
 PO45   Minimal residual disease as a predictive marker of early relapse and dissemination in breast cancer. Michaela Cabinakova, CZ
 PO46   The FAS −670A/G gene polymorphism as biomarker of clinical outcome of breast carcinoma: association with distant metastasis and survival. Wijden Mahfoudh, TN
 PO47   Evaluation of  HER2/neu expression in breast cancer bone metastases. Jose Juan Illarramendi, ES
 PO48   Prognostic role of Ki67 determined on metastatic tissue of patients with advanced breast cancer. Claudette Falato, SE
 PO50   E-Cadherin in metastatic and non metastatic reast carcinoma. Maman Abdurahman, ID
 PO51   Correlation between GRP 78 expression with neoadjuvant chemoterapy at locally advanced breast cancer. Kiki Rizky, ID
 PO54   Treatment of locally advanced breast cancer: a Tunisian experience. Samir Hidar, TN
 PO55   The role of in-vitro high resolution magic angle proton magnetic resonance spectroscopy (HRMAS) in breast cancer- a pilot study. Surender Kumar, IN
 PO57   Novel strategy to restore the activity of taxanes: a multicenter phase II study of combination therapy with taxanes and toremifene at 120 mg for advanced/recurrent breast cancer. (Kinki Multidisciplinary Breast Oncology Group: KMBOG0612). Takahiro Nakayama, JP
 PO58    Neoadjuvant chemotherapy and surgical options for locally advanced breast cancer: A single institution experience Mohamed Abou Elmagd Salem, EG
 PO59   Features of recurrence of triple negative (TN) non-metastatic breast cancer (NMBC)  patients: A single institution study. Ashley Alarcon-Rozas, PE
 PO60    Final results of a pilot study of pathological complete response (pCR) in LABC patients treated with AC x 4 dose dense followed by weekly paclitaxel x 12 with capecitabine. Ashley Alarcon-Rozas, PE
 PO61   New trends for surgical treatment of locally advanced breast cancer. Angelo Gustavo Zucca Matthes, BR
 PO62   Breast cancer: Is there any difference in younger women? Miguel Abreu, PT
 PO63    Ethnic differences in survival of breast cancer patients in Kazakhstan. Nikolay Malyshev, KZ
 PO64    Surgical options in the management of patients with locally advanced breast cancer in a resource constrained setting: the Lagos University Teaching Hospital (luth) experience. Abdul Razzaq Lawal, NG
 PO65    Interstitial lung disease associated with docetaxel in Japanese breast cancer patients - A retrospective study at a single institution. Akihiko Shimomura, JP
 PO66    Nurse's role in the interventional diagnostic procedures of breast lesions. Biljana Dabic, BA
 PO68   Long term recovery of shoulder motion capacity after mastectomy is significantly worse in women with advanced breast cancer. Sophie Derchain, BR
 PO69   Selected case reports of treatment of locally advanced breast cancer - sanative mastectomy. (This paper was produced with the support of the IGA NS 10238-3/2009 grant). Monika Cerna, CZ
 PO70    Recurrent disease in 50 breast cancer patients with pathological complete response (pCR) to chemotherapy. Yoshiya Horimoto, JP
 PO71    Analysis of factors predicting response to first line endocrine therapy (HT) in menopausal patients with luminal-type advanced breast cancer (ABC). Olexiy Aseyev, UA
 PO73    Electrochemotherapy with bleomycin in the treatment of cutaneous metastases from breast cancer and resistant to standard therapies: a case report. Riccardo Bussone, IT
 PO74   Long-term control of brain metastases in breast cancer patients by lapatinib. Petra Tesarova, CZ
 PO75   Comparing local effect radiotherapy and neoadjuvant chemotherapy in locally advanced breast cancer at Hasan Sadikin Hospital. Yohana Azhar, ID
 PO76   Comprehensive cancer therapy in metastatic breast cancer- a pilot project of early integration of palliative medicine. Rachel Wuerstlein, DE
 PO77   Disease-specific guidelines: a concept of facilitating early integration of palliative care into breast cancer therapy. Rachel Wuerstlein, DE
 PO78   Clinical efficacy of bevacizumab plus taxane in metastatic breast cancer in a single  institution. Serafin Morales, ES
 PO79   Differences in metastatic potential in HER2 positive and triple negative inflammatory breast cancer. Daniela Kolarevic, RS
 PO80   Advanced breast cancer with oligometastasis. Quality of life in long term survivors following aggressive treatments. Single clinician's experience. Thomas Varughese, IN
 PO81   Salvage mastectomy for ipsilateral breast tumor recurrence after breast conserving therapy. Abdel Hamid Ezzat, EG
 PO82    Chronology of HER2 disease. Junichiro Watanabe, JP
 PO83   Predicting the risk of recurrence in women with stage III breast cancer. Chia Hau Ng, SG
 PO84   One UK Breast Unit's experience of GP 2 week wait referrals to breast care clinic - are they appropriate? Jennifer Yin, UK
 PO85   Breast cancer metastasis in thyroid gland  - report of three cases. Inês Romero, PT
 PO86    A characteristic of stage3 breast cancer that received neoadjuvant chemotherapy: pCR is expected similar to stage2,  brain metastases in the pCR cases are highly in  Her2-type and  significantly has a poor prognosis in non-pCR cases. Hiroshi Kaise, JP
 PO87   Clinical symptoms of bone marrow metastases in breast cancer patients. Maria Rodionova, RU
 PO88   Implementation of palliative care in German breast centers - a national questionnaire, interim results. Rachel Wuerstlein, DE
 PO89   Identifying those at high risk of brain metastasis from breast cancer. Ern Yu Tan, SG
 PO90   Primary chemotherapy for women presenting with inoperable breast tumours. Yia Swam Tan, SG
 PO91   Descriptive study of metastatic breast cancer patients with long-term progression-free survival during first-line hormone therapy: Experience from a single cancer center. Jose Juan Illarramendi, ES
 PO92    Spatial analysis in mortality rate for female breast cancer in Rio de Janeiro – Brazil. Marcelo Bello, BR
 PO93    The impact of breast separation on radiation dose delivery to the ipsilateral lung as a result of respiratory motion quantified using free breathing and 4D-CT-based planning for radiotherapy to whole breast and regional lymphatics in patients with locally advanced breast cancers: results of Weill Cornell Medical College, New York. T.E. Heineman, US
 PO94   Significant survival improvement and prognostic factors of recurrent breast cancer after approval third generation aromatase inhibitors and trastuzumab. Mayumi Ishida, JP
 PO95   Metastatic male breast cancer. Irina Khachaturyan, AM
 PO96    Metastatic breast cancer at diagnosis - a Breast Unit 5 year experience. André Costa-Pinho,PT
 PO97    Trends in incidence of late-stage breast cancer following introduction of organised mammography screening in Italy by Impact Working Group. Fabio Falcini, IT
 PO98    Survival of women diagnosed with compression syndrome due to bone metastasis secondary to breast cancer. Anke Bergmann, BR
 PO99    Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Sally Garnett, UK
 PO100    A hospital-based study of factors related to late stage diagnosis in a series of 44,085 breast cancer patients in Brazil. Luiz Claudio Thuler, BR
 PO101    Response to subsequent endocrine therapy in patients treated with fulvestrant 500mg or anastrozole: results from FIRST. John F.R. Robertson, UK
 PO102   Benefit of continuing trastuzumab beyond progression in her2-positive metastatic breast cancer (mbc) is independent of the chemotherapy partner: message from a single-centre retrospective study. Raffaella Palumbo, IT
 PO103   Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: A single institution experience.  Shintaro Takao, JP
 PO104    Study of mutations in BRCA1 and BRCA 2 gene among the breast cancer patients in Eastern Indian population. Abhijit Chakraborty, IN
 PO105   The vertical rectus abdominis myocutaneous (VRAM) flap is the preferred means of post-mastectomy defect cover for large breast tumours. Tse Han Loong, SG
 PO106   Liver metastasis from breast cancer: suitability for resection? Yia Swam Tan, SG
 PO107   Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE study group. Javier Cortes, US
 PO108   A case report of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy. Sara Meireles, PT
 PO109   Effective management of malignant pleural effusion in advanced breast cancer patients by intrapleural chemotherapy with cisplatin and gemcitabine. Elena Shakhnovich, RU
 PO110   Epidemiological, genetic, histological and clinical aspects of breast cancers in population of Czech women. Marek Svoboda, CZ
 PO121   An explorative study of the information routinely given to younger women diagnosed with metastatic breast cancer in relation to pregnancy and contraception. Maria Leadbeater, UK
 PO122   Integration of complementary therapies for treatment of advanced breast. Ann Fonfa, US
 PO123   The Metastatic Breast Cancer Network:  a proactive voice of those living with metastatic breast cancer. Shirley Mertz, US
 PO124   Partnering with patients: what doctors need to know about patient experience of advanced breast cancer. Dikla Benzeevi, US
 PO125   Addressing the psychosocial gap: What are the psychosocial needs of people living with ABC and what can psycho-oncology services offer? Luzia Travado, PT

VAT/NIPC 515 732 230